Table 1

List of clinical targeted therapeutic agents inducing an adaptive response in cancer cells

Adaptive response	Drugs (generic name)	Trade name	Drug type	Target protein	Cancer	Reference
Autophagy	Afatinib	Gilotrif	Tyrosine kinase inhibitor	EGFR	NSCLC	²⁰⁴
	Bevacizumab	Avastin	Monoclonal antibody	VEGF-A	CRC	³⁰
					GBM	²⁰⁵
	Bortezomib	Velcade	Proteasome inhibitor	26S proteasome	Breast cancer	^97,206
	Cetuximab	Erbitux	Fv (variable, antigen-binding) regions of monoclonal antibody	EGFR	Lung cancer, CRC	⁵⁹
	Dasatinib	Sprycel	Tyrosine kinase inhibitor	BCR/ABL, Src family	NSCLC	²⁰⁷
	Gefitinib	Iressa	Tyrosine kinase inhibitor	EGFR	Breast cancer	⁶⁵
	Idelalisib	Zydelig	PI3K inhibitor	P110 delta	CML	⁹⁸
	Lapatinib	Tykerb	Tyrosine kinase inhibitor	EGFR, HER2	Breast cancer	²⁰⁸
					HCC	²⁰⁹
	Osimertinib	Tagrisso	Tyrosine kinase inhibitor	EGFR	NSCLC	²¹⁰
	Sorafenib	Nexavar	Tyrosine kinase inhibitor	Raf, PDGF, VEGFR2/3, Kit	RCC	²¹¹
	Sunitinib	Sutent	Tyrosine kinase inhibitor	PDGFR, VEGFR, KIT	HCC	²¹²
					mRCC	²¹³
					PanNET	²¹⁴
	Trametinib	Mekinist	MEK kinase inhibitor	MEK1/2	Melanoma	²¹⁵
					Leukemia	²¹⁶
	Trastuzumab	Herceptin	Monoclonal antibody	HER2	Breast cancer	^217–219
	Vemurafenib	Zelboraf	Competitive kinase inhibitor	BRAF (V600E)	Melanoma	²²⁰
	Vismodegib	Erivedge	Cyclopamine-competitive antagonist	SMO	CML	²²¹
ER stress	Bortezomib	Velcade	Proteasome inhibitor	26S proteasome	Breast cancer	⁹⁷
	Trastuzumab	Herceptin	Monoclonal antibody	HER2	Breast cancer	²²²
SASP	Sunitinib	Sutent	Tyrosine kinase inhibitor	PDGFR, VEGFR, KIT	Breast cancer	¹⁹³

EGFR, epidermal growth factor receptor; VEGF-A, vascular endothelial growth actor A; HER2, human epidermal growth factor receptor 2; MEK1/2, mitogen-activated protein kinase kinase 1/2; VEGFR, vascular endothelial growth factor receptor; SMO, smoothened; NSCLC, non-small cell lung cancer; CRC, colorectal cancer; GBM, glioblastoma; CML, chronic myeloid leukemia; HCC, hepatocellular carcinoma; mRCC, metastatic renal cell carcinoma; PanNET, pancreatic neuroendocrine tumors.